Journal of radiological science and technology (대한방사선기술학회지:방사선기술과학)

Korean Society of Radiological Science (대한방사선과학회)
권호 표지

Clinical Outcomes and Prognosis of Patients with Stent Fracture after Successful Drug-Eluting Stent Implantation

관상동맥 약물 방출 스텐트 삽입 후 스텐트 골절에 대한 임상결과 및 예후

  • 김인수 (전남대학교병원 심혈관센터) ;
  • 한재복 (동신대학교 방사선학과) ;
  • 장성주 (동신대학교 방사선학과)
  • Received : 2014.02.27
  • Accepted : 2014.06.02
  • Published : 2014.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Many studies have suggested that in the era of Drug-Eluting Stents(DES) are one of the causes of In-Stent Restenosis(ISR) of Stent Fracture(SF). The present study sought to evaluate clinical characteristics of patients with stent fracture after successful DES implantation. The 4,701 patients were selected for analysis who underwent a follow-up coronary angiography irrespective of ischemic symptoms. The overall incidence of SF was 32 patients(male:female=19:13, Av. age $62.44{\pm}9.8$year, 0.68%). Fractures of Sirolimus-Eluting Stents(SES), Paclitaxel-Eluting Stents(PES), Biolimus A9-Eluting Stents(BES), Everolimus-Eluting Etents(EES), Endothelial Progenitor Cell Capture Stent(EPC) and Zotarolimus-Eluting Stents(ZES) are accounted for 19(59.4%), 9(28.1%), 2(6.3%), 1(3.1%), 1(3.1%) and 0(0%) respectively. SF developed in the left Anterior Dscending(LAD) artery in 16 patients(50%) and in complex(type B2, C) lesions in 25 patients(69.4%). Ten patients were treated with heterogenous DES, the rest being treated with either homogenous DES(3 patients), plain old balloon angioplasty(3 patients), or conservative medical treatment(17 patients). None of the patients with SF suffered from cardiac death during a follow-up period of $32.9{\pm}12.4$ months. The overall rate of DES fracture over up to 3.7 years of follow-up was 0.68% with higher incidence in SES than in PES. SF frequently occurred in the LAD artery and in complex lesions. Of the patients with SF, coronary intervention was performed only when the binary restenosis lesion was significant. During the follow-up, patients with SF have continued on combination antiplatelet therapy. There is a very low rate of major adverse cardiac events(post-detection of SF), especially cardiac death associated with SF.

본 연구에서는 관상동맥 중재술로 관상동맥 약물방출 스텐트(drug-eluting stent, DES) 삽입 후 스텐트 골절에 대한 임상적 특성, 결과 및 예후에 대하여 연구하였다. 약물방출 스텐트 시술을 받고 추적 관상동맥조영술을 실시한 4,701명 환자에서 스텐트 골절이 발생한 환자는 32명(남:여=19:13, 평균연령 $62.44{\pm}9.8$세, 0.68%)이었다. DES의 종류별 스텐트 골절의 빈도는 SES(sirolimus- eluting stents) 19(59.4%), PES(paclitaxel-eluting stents) 9명(28.1%), BES(biolimus A9-eluting stents) 2명(6.3%), EES(everolimus-eluting stents) 1명(3.1%), EPC(endothelial progenitor cell capture stent) 1명(3.1%), ZES(zotarolimus-eluting stents) 0명(0%) 이었다. 표적 병변은 우관상동맥 13명(40.6%) 좌전하행지 16명(50.0%), 좌회선지 3명(9.4%)이었다. 각 혈관의 병변 형태는 복잡병변인 B2, C형이 25명(69.4%)이었다. 스텐트 골절 환자 중 스텐트 내 협착은 17명(53.1%)이었으며, 스텐트 골절 병변에 대한 치료는 내과적 관찰 16명(50.0%), 동종의 관상동맥 DES 시술 3명(9.4%), 이종의 관상동맥 DES 시술 10명(31.3%), 관상동맥 풍선 확장술 3명(9.4%)이었다. 추적검사에서는 $32.9{\pm}12.4$개월 동안 스텐트 골절로 인한 사망을 포함한 심장사는 발생하지 않았다. 결론적으로 관상동맥 중재술로 관상동맥 DES를 시술받은 추적관찰 대상 환자에서 3.7년 추적관찰 기간 동안 스텐트 골절 발생률은 0.68%로 나타났으며, PES보다 SES에서 많은 발생 빈도를 보였다. 좌전하행지와 복잡병변에 대한 시술 후 스텐트 골절이 많이 발생하였다. 또한 스텐트 골절 정도와 협착 병변이 중대한 경우에만 관상동맥 중재술을 실시하였으며, 추적관찰 기간 중 스텐트 골절이 있는 환자는 병용 항혈소판 요법을 지속적으로 투여하였다. 특히 사망을 포함한 주요 심장사건에 관련하여 스텐트 골절과 연관된 심장사의 발생률은 매우 낮은 것으로 나타났다. 본 연구를 통해서 스텐트가 가지고 있는 특성 스텐트 디자인이 폐쇄형(closed cell) 디자인 SES에서 발생 빈도가 높음을 제시함으로써 스텐트 개발에 도움이 될 거라 판단된다.

Keywords

References

  1. Kim IS, Han JB, Jang SJ, Jang YI: The study on the independent predictive factor of restenosis after percutaneous coronary intervention used drug-eluting stent : case on MDCT calcium-scoring implementation patient. Journal of radiological science and technology, 33:37-44, 2010
  2. Morice MC, Serruys PW, Sousa JE, et al: A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med, 346:1773-80, 2002 https://doi.org/10.1056/NEJMoa012843
  3. Lemos PA, Saia F, Ligthart JM, et al: Coronary restenosis after sirolimuseluting stent implantation: morphological description and mechanistic analysis from a consecutive series of cases. Circulation, 108:257-60, 2003 https://doi.org/10.1161/01.CIR.0000083366.33686.11
  4. Sianos G, Hofma S, Ligthart JM, et al: Stent fracture and restenosis in the drug-eluting stent era. Catheter Cardiovasc Interv, 61:111-6, 2004 https://doi.org/10.1002/ccd.10709
  5. Park JS, Shin DG, Kim YJ: Fractured DES with a patent coronary artery: clinical implications. J Invasive Cardiol, 19:E43-5,2007
  6. Vaknin-Assa H, Assali A, Fuchs S, Kornowski R: An unusual cluster of complications following drug-eluting stenting: stent fracture, peri-stent aneurysm and late thrombosis. Isr Med Assoc J, 9:331-2, 2007
  7. Lee SE, John SH, Lim JH, Rhew JY: A case of very late stent thrombosis associated with multiple stent fractures and peri-stent aneurysm formation after sirolimus-eluting stent implantation. Circ J, 72:1201-4, 2008 https://doi.org/10.1253/circj.72.1201
  8. Okamura T, Hiro T, Fujii T, et al: Late giant coronary aneurysm associated with a fracture of sirolimus eluting stent: a case report. J Cardiol, 51:74-9, 2008 https://doi.org/10.1016/j.jjcc.2007.11.002
  9. Chung WS, Park CS, Seung KB, et al: The incidence and clinical impact of stent strut fractures developed after drug-eluting stent implantation. Int J Cardiol, 125:325-31, 2008 https://doi.org/10.1016/j.ijcard.2007.02.033
  10. Aoki J, Nakazawa G, Tanabe K, et al: Incidence and clinical impact of coronary stent fracture after sirolimus-eluting stent implantation. Catheter Cardiovasc Interv, 69:380-6, 2007 https://doi.org/10.1002/ccd.20950
  11. Umeda H, Gochi T, Iwase M, et al: Frequency, predictors and outcome of stent fracture after sirolimus eluting stent implantation. Int J Cardiol, Epub ahead of print, 2008
  12. Allie DE, Hebert CJ, Craig M: Nitinol stent fractures in the SFA. Endovasc Today, 22-34, 2004
  13. Scheinert D, Scheinert S, Sax J, et al: Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol, 45:312-5, Available online, 2005 https://doi.org/10.1016/j.jacc.2004.11.026
  14. Chung WS, Park CS, Seung KB, et al: The incidence and clinical impact of stent strut fractures developed after drug-eluting stent implantation. Int J Cardiol, 125: 325-31, 2008 https://doi.org/10.1016/j.ijcard.2007.02.033
  15. Kim HS, Kim YH, Lee SW, et al: Long-DES-II study investigators. Incidence and predictors of drug-eluting stent fractures in long coronary disease. Int J Cardiol, 133: 354-8, 2009 https://doi.org/10.1016/j.ijcard.2008.01.005
  16. Canan T, Lee MS: Drug-eluting stent fracture: incidence, contributing factors, and clinical implications. Catheter Cardiovasc Interv, 75:237-45, 20:305-13, 2010 https://doi.org/10.1002/ccd.22212
  17. Nakazawa G, Finn AV, Vorpahl M, et al: Incidence and predictors of drug-eluting stent fracture in human coronary artery a pathologic analysis. J Am Coll Cardiol, 54:1924-31, 2009 https://doi.org/10.1016/j.jacc.2009.05.075
  18. Park KW, Park JJ, Chae IH, et al: Clinical Characteristics of Coronary Drug-Eluting Stent Fracture:Insights from a Two-Center DES Registry. J Korean Med Sci, 26: 53-58, 2011 https://doi.org/10.3346/jkms.2011.26.1.53
  19. Liao R, Green NE, Chen SY: Messenger JC, Hansgen AR, Groves BM, Carroll JD. Three-dimensional analysis of in vivo coronary stent-coronary artery interactions. Int J Cardiovasc Imaging, 20:305-13, 2004 https://doi.org/10.1023/B:CAIM.0000041950.84736.e6
  20. Kim JS, Yoon YW, Hong BK, et al: Delayed Stent Fracture after Successful Sirolimus-Eluting Stent(Cypher(R)) Implantation. Korean Circ J, 36(6):443-449, 2006 https://doi.org/10.4070/kcj.2006.36.6.443
  21. Oh JH, An SM: The value of calcium-scoring CT for ischemic cardiovascular disease screening. Journal of radiological science and technology, 32:69-78, 2009